Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
An Overview of Targeted Alpha Therapy with <sup>225</sup>Actinium and <sup>213</sup>Bismuth
353
Zitationen
6
Autoren
2018
Jahr
Abstract
Background: Recent reports of the remarkable therapeutic efficacy of 225Ac-labeled PSMA- 617 for therapy of metastatic castration-resistant prostate cancer have underlined the clinical potential of targeted alpha therapy. Objective and Conclusion: This review describes methods for the production of 225Ac and its daughter nuclide 213Bi and summarizes the current clinical experience with both alpha emitters with particular focus on recent studies of targeted alpha therapy of bladder cancer, brain tumors, neuroendocrine tumors and prostate cancer.
Ähnliche Arbeiten
Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.
1981 · 14.249 Zit.
The nuclear receptor superfamily: The second decade
1995 · 6.967 Zit.
A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity
1984 · 5.023 Zit.
Screening λgt Recombinant Clones by Hybridization to Single Plaques in Situ
1977 · 4.664 Zit.
Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67.
1984 · 4.206 Zit.